It is expected that tumor expression of PD-L1 may be a predictive biomarker because it reflects protein expression levels of the target of anti-PD-1 agents, and effective blocking action requires pre-existing PD-L1−PD-1 interaction in tumors. This evidence concerns the gene CD274 and neoplasm.